Volume 10, Number 4, April 2004

Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

Emily L.C. Tan,* Eng Eong Ooi,† Chin-Yo Lin,* Hwee Cheng Tan,† Ai Ee Ling,‡ Bing Lim,* and Lawrence W. Stanton*
*Genome Institute of Singapore, Singapore; †National Environmental Agency, Singapore; and ‡Singapore General Hospital, Singapore

Figure 2. Dose-response curves for Alferon (A), Betaferon (B), and Multiferon (C) as determined by plaque reduction assays. IC₅₀ (50% inhibitory concentration) and IC₉₅ (95% inhibitory concentration) values were calculated by using the fitted functions describing the curves.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed March 2, 2004

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention